SNORA79: A Small Nucleolar RNA with Potential as a Drug Target or Biomarker

Target Name: SNORA79

NCBI ID: G677845

SNORA79

Other Name(s): small nucleolar RNA, H/ACA box 79 | SNORA79A | ACA65 | Small nucleolar RNA, H/ACA box 79

SNORA79: A Small Nucleolar RNA with Potential as a Drug Target or Biomarker

Introduction

Small nucleolar RNA (snRNA) is a non-coding RNA molecule that plays a crucial role in the regulation of gene expression in eukaryotic cells. One of the key functions of snRNA is to interact with the host RNA binding proteins, which in turn regulate gene expression. H/ACA box 79 (SNORA79) is a specific snRNA that has been identified as a potential drug target or biomarker.

The H/ACA box 79 is a 24 nucleotide long RNA molecule that is located within the H/ACA box 79 gene on chromosome 18. It is expressed in a variety of tissues and cells, including the brain, heart, liver, and pancreas. The function of SNORA79 is not well understood, but it is involved in the regulation of gene expression and has been implicated in a number of cellular processes, including cell growth, apoptosis, and inflammation.

Potential Drug Target

The H/ACA box 79 is a potential drug target due to its unique structure and the involvement of several diseases that are associated with the over-expression of SNORA79. One of the main reasons for its potential as a drug target is its high stability, which allows it to be used as a drug or biomarker in both in vitro and in vivo studies. Additionally, the H/ACA box 79 is well conserved across different species, which suggests that it is a good candidate for drug targeting.

Another potential mechanism by which SNORA79 may be targeted as a drug is its role in the regulation of cellular signaling pathways. The H/ACA box 79 has been shown to play a role in the regulation of several signaling pathways, including the TGF-β pathway , which is involved in cell growth and differentiation. Additionally, the H/ACA box 79 has been shown to be involved in the regulation of cell apoptosis, which is a critical mechanism that helps cells to remove damaged or dysfunctional proteins.

Biomarker

SNORA79 has also been identified as a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. This is because the H/ACA box 79 is expressed in a variety of tissues and cells and is highly stable, which allows it to be used as a biomarker in a variety of settings. For example, it has been used as a biomarker to assess the effectiveness of anti-cancer drugs in animal models of cancer. Additionally, the H/ACA box 79 has been shown to be involved in the regulation of cellular signaling pathways, which may be relevant to neurodegenerative diseases.

Conclusion

SNORA79 is a small nucleolar RNA that has been identified as a potential drug target or biomarker. Its unique structure and the involvement of several diseases associated with its over-expression make it an attractive candidate for drug targeting. Further research is needed to fully understand the function of SNORA79 and its potential as a drug target or biomarker.

Protein Name: Small Nucleolar RNA, H/ACA Box 79

The "SNORA79 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORA79 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets